PARIS/BOSTON (Reuters) - Biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially ...

PHILADELPHIA (Reuters) - Biotechnology company Genzyme Corp may be holding out for more money from suitor Sanofi-Aventis , but will find it difficult to persuade investors it is better off on its own.

In an ironic twist, Genzyme (www.genzyme.com) first battled through its acquisition of Bioenvision and is now basking in the glory of speculations over big pharma’s interest in gobbling up biologic ...

Sanofi-aventis CEO Chris Viebacher outlined the research and development strategy that led to the <a target="_blank" href="http://www.masshightech.com/stories/2011/02 ...

CAMBRIDGE, Mass. – Genzyme Corp. (Nasdaq: GENZ) today announced that it has established a program to participate in efforts to discover and advance novel treatments for neglected diseases affecting ...

What would you do if you operated a French pharmaceutical company that lost patent protection on its key drugs, laid off 2,500 workers by conference call, seen its most hyped cancer drug fail to meet ...

How do you whittle 35 years of headlining business news down to a couple thousand words and a few pages? You don't. But here, we take our best shot to highlight the companies, individuals, and moments ...

Bayer stands to earn up to $1.9 billion dependent on approval and sales achievements. Genzyme is taking over worldwide rights from Bayer HealthCare covering Campath® (alemtuzumab), which is approved ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Less than two months after Genzyme’s newest drug to treat ...

(AP) — Biotechnology company Genzyme Corp. said Friday it hired Ron Branning as senior vice president of global product quality. Branning will oversee quality control for Genzyme products made at 17 ...

A 25,000-square-foot office building in Framingham that formerly housed the drugmaker Genzyme has sold for $3.2 million. The buyer is a limited liability corporation, called 11 Pleasant Street ...

Sanofi-Aventis agreed to buy Genzyme Corp., ending a nine-month pursuit of the U.S. biotechnology company with a sweetened offer of at least $20.1 billion that gives France's biggest drugmaker ...